TRB Wealth Management LLC Cuts Holdings in Eli Lilly and Company $LLY

Key Points

• TRB Wealth Management cut its Eli Lilly stake by 36%. The firm sold 1,585 shares during the second quarter and retained 2,820 shares valued at approximately $3.38 million, representing 0.5% of its portfolio.
• Analysts remain broadly bullish on LLY. Twenty-four analysts rate the stock a Buy and the consensus price target is $1,292.18, while recent quarterly results exceeded expectations with $8.38 in EPS and $22.97 billion in revenue.
• Growth prospects are strong but valuation and GLP-1 coverage remain risks. Zepbound data and pipeline developments support the outlook, but payer concerns, the stock’s elevated valuation, and recent insider selling could weigh on sentiment.

TRB Wealth Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 36.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,820 shares of the company's stock after selling 1,585 shares during the quarter. Eli Lilly and Company accounts for 0.5% of TRB Wealth Management LLC's investment portfolio, making the stock its 26th biggest position. TRB Wealth Management LLC's holdings in Eli Lilly and Company were worth $3,382,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $12,976,634,000. J. Stern & Co. LLP grew its holdings in shares of Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock worth $4,047,245,000 after purchasing an additional 4,038,502 shares during the period. Cardano Risk Management B.V. grew its holdings in shares of Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the period. Fifth Third Bancorp increased its position in Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LLY. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research report on Monday, July 13th. Rothschild & Co Redburn lifted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,419.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Finally, Barclays increased their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $1,292.18.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Zepbound real-world data: A study found that sustained Zepbound use among adults over 55 with overweight or obesity was associated with fewer hospital and emergency-room visits and lower healthcare costs. The findings could support broader payer acceptance and strengthen the case for Medicare coverage. Zepbound linked to lower healthcare costs
• Positive Sentiment: Alzheimer’s diagnostic milestone: The FDA cleared a blood test developed by Lilly and Roche to help identify Alzheimer’s-related amyloid pathology. A less-invasive test could expand access to diagnosis and support demand for Lilly’s Alzheimer’s franchise, including Kisunla. Eli Lilly clears hurdle in Alzheimer’s fight
• Positive Sentiment: Pipeline diversification: Oncology revenue increased 11% in the first half of 2026, while newer products and pipeline candidates may help Lilly reduce its dependence on GLP-1 medicines. Lilly also advanced brenipatide into a Phase 3 depression study, adding another potential long-term growth opportunity. Lilly oncology portfolio growth
• Neutral Sentiment: Valuation and positioning: Lilly remains near its 52-week high, and analysts’ median price target of approximately $1,348.50 implies additional upside. However, the elevated valuation leaves the stock vulnerable to sharp reactions when growth or reimbursement concerns emerge.
• Negative Sentiment: GLP-1 coverage concerns are weighing on sentiment: Employer-benefit surveys and reports that some companies may reduce coverage for weight-management drugs have renewed fears that payer restrictions could slow Zepbound and future oral obesity-drug adoption. The decline appears more sentiment-driven than a response to weaker operating results. GLP-1 coverage concerns
• Negative Sentiment: Cost-savings evidence has limitations: Lilly-sponsored research supports Zepbound’s medical and economic value, but critics note that the analysis measured healthcare savings before accounting for the drug’s price. This may weaken the immediate impact of the findings in payer negotiations. Lilly cost-saving study limitations

Eli Lilly and Company Stock Down 1.2%

Shares of Eli Lilly and Company stock opened at $1,175.01 on Friday. The business has a 50-day moving average of $1,187.82 and a 200-day moving average of $1,064.57. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market capitalization of $1.11 trillion, a PE ratio of 39.43, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $712.05 and a 1-year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company's revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is presently 23.22%.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source